COPENHAGEN, Denmark, May 4, 2026 – Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, will provide a business update and report its first quarter 2026 financial results on Thursday May 7, 2026, before opening of the Nasdaq CM. Evaxion’s Executive Management will host a conference call and webcast the same day at 14:30 CET/08:30 EST, presenting the update and results as well as taking questions. To join the conference call, listen to the presentation and ask verbal questions, please register in advance via this link to receive the dial-in telephone numbers and a unique PIN code. The call can be accessed 15 minutes prior to the start of the live event. To join the webcast, please click on this link. The webcast recording will be available...

Total 1Q 2026 net product revenue of $191.2 million, representing 57% year-over-year growth AUVELITY® 1Q 2026 net product sales of $153.2 million, representing 59% year-over-year growth SUNOSI® 1Q 2026 net product revenue of $33.9 million, representing 34% year-over-year growth SYMBRAVO® 1Q 2026 net product sales of $4.1 million AUVELITY approved for the treatment of agitation associated with dementia due to Alzheimer’s disease NDA for AXS-12 for the treatment of cataplexy in narcolepsy submitted to the FDA AXS-20 (balipodect), potentially first-in-class, pre-Phase 3, PDE10A inhibitor for schizophrenia and Tourette syndrome, added to pipeline Company to host conference call today at 8:00 AM Eastern NEW YORK, May 04, 2026 (GLOBE NEWSWIRE) — Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in...

– Total net sales of $140.9 million, compared to $137.1 million in prior year first quarter –– Net income of $0.8 million, up from a net loss of ($0.8) million in prior year first quarter –– EBITDA of $4.8 million, up from $3.5 million in prior year first quarter –– Confirms full-year Outlook – – Board of Directors approves $0.14 per share quarterly dividend –ST. PETERSBURG, Fla., May 04, 2026 (GLOBE NEWSWIRE) — Superior Group of Companies, Inc. (NASDAQ: SGC) (the “Company”), today announced its first quarter 2026 results. “Against a still uncertain economic backdrop, our first quarter results show that we are continuing to move Superior Group of Companies in the right direction, even as there is still work to reach the level of performance we are targeting,” said Michael Benstock, Chief Executive Officer....

$116.4 million in 1Q VYJUVEK global revenue and $846.7 million since launch Enrollment complete in KB803 (corneal abrasions in DEB patients) registrational study On track for KB803 and KB801 (NK) registrational data readouts in 2026 FDA grants platform technology designation for KB407 (CF) and KB111 (HHD) Strong balance sheet, ending the quarter with $1.0 billion in cash and investments PITTSBURGH, May 04, 2026 (GLOBE NEWSWIRE) — Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) today reported financial results for the first quarter ending March 31, 2026 and provided a business update. “Following a successful 2025, we are entering 2026 with strong momentum, including two potential registrational study readouts and continued global expansion for VYJUVEK,” said Krish S. Krishnan, Chairman and Chief Executive Officer of Krystal...

MIAMI, May 04, 2026 (GLOBE NEWSWIRE) — Norwegian Cruise Line Holdings Ltd. (NYSE: NCLH) (together with NCL Corporation Ltd. (“NCLC”), “Norwegian Cruise Line Holdings”, “Norwegian”, “NCLH” or the “Company”) today reported financial results for the first quarter ended March 31, 2026 and provided guidance for the second quarter and full year 2026. HighlightsFirst quarter total revenue grew 10% to $2.3 billion. GAAP net income was $105 million, with EPS of $0.23. Delivered Adjusted EBITDA1 of $533 million in first quarter 2026, exceeding guidance, and representing an increase of 18% compared to 2025. Adjusted Net Income more than doubled to $108 million. Adjusted EPS increased $0.13 to $0.23. Company lowered full year 2026 guidance with Adjusted EPS expected to be $1.45 to $1.79. Company took delivery of Norwegian Luna, featuring...

WATERLOO, Ontario and ATLANTA, May 04, 2026 (GLOBE NEWSWIRE) — Descartes Systems Group (TSX: DSG) (Nasdaq: DSGX), the global leader in uniting logistics-intensive businesses in commerce, is scheduled to report its first quarter fiscal 2027 financial results after market close on Wednesday, June 03, 2026. Members of Descartes’ executive management team will host a conference call to discuss the company’s financial results at 5:30 p.m. ET on Wednesday, June 03, 2026. Designated numbers are +1 289 514 5100 or Toll-Free for North America at +1 800 717 1738, using conference ID 44762. The company will simultaneously conduct an audio webcast on the Descartes website at www.descartes.com/descartes/investor-relations. A phone conference dial-in or webcast log-in is required approximately 10 minutes before the start. Replays...

ALK delivers 18% organic revenue growth with operating profit (EBIT) up 22% in Q1 Q1 saw broad-based growth across key categories and regions with sustained, strong momentum in tablet sales in Europe and North America.  Operating profit increased driven by sales growth, improved gross margin, and scale benefits, resulting in an EBIT margin of 32%. Free cash flow doubled. The full-year outlook has been upgraded.    Performance highlights Comparative figures for Q1 2025 are shown in brackets. Growth rates are stated in local currencies (l.c.), unless otherwise indicated.Revenue increased by 18% to DKK 1,771 million (1,522) on double-digit growth across regions and products.      Tablet sales grew by 18% to DKK 1,004 million (857), driven by a 26% growth both in Europe and North America reflecting growing patient and prescriber bases. International...

Statkraft AS will publish its first quarter 2026 results on Thursday 7 May 2026 at 08:00 a.m. CEST. The quarterly report and presentation material will be made available on Statkraft’s website https://www.statkraft.com/IR/ and through Oslo Stock Exchange’s information system (NewsWeb) www.newsweb.no. WebcastA webcast presentation of the results will be held at 10:30 a.m. CEST at www.statkraft.com. The presentation will be held in English. For further information, please contact:Arild Ratikainen, Investor contact, tel.: +47 971 74 132, e-mail: arild.ratikainen@statkraft.com

Facephi Ends 2025 with Solid Performance Across All Key Metrics: Double-Digit Revenue and Tripple-Digit EBITDA Growth. It Returns to Profitability2025: a catalyst year, marking the transformation from a primarily biometric vendor to a comprehensive 360º AI-driven digital identity and fraud-prevention platform. Revenue and EBITDA grew 24.6% and 917.5% YoY respect. Profit after Tax positive of €0.4M (or +€1.5M on a constant currency (CC) basis), a significant turnaround from negative of -€8.9M in 2024.    Cash flow improved YoY by €2,2M (vs. -€4.6M in 2024 and -€9.0M in 2023), underscoring the trajectory toward FCF significantly positive in 2026. On a CC basis, it would have been -€0.3M. The Company reiterates its guidance for 2026: Revenue €46.2m (+28.4%), EBITDA €11.0M (+5.0%) and FCF of +€4.3M.Alicante, May 04, 2026 – Facephi...

Irvine, California, May 01, 2026 (GLOBE NEWSWIRE) — Pacific Health Care Organization, Inc., (the “Company”) (OTCQB: PFHO) filed yesterday with the Securities and Exchange Commission (the “SEC”) its quarterly report on Form 10-Q announcing its financial results for the quarter ended March 31, 2026. Results The Company reported total revenues of $1,497,704 for the quarter ended March 31, 2026, compared to $1,818,814 for the quarter ended March 31, 2025. The Company reported income from operations of $172,684 for the quarter ended March 31, 2026, compared to income from operations of $314,419 for the quarter ended March 31, 2025. The Company realized net income of $193,669 or $0.02 per weighted average share outstanding, basic and diluted, for the quarter ended March 31, 2026, compared to net income of $292,663 or $0.02 per weighted...